Moderna is trading 4.07% up at $143.61, with no new August 31 company announcement clearly explaining the intraday gain.
- The stock is recovering after closing at $137.99 on August 28.
- Recent trading has focused on the upsized $2.6 billion convertible-note offering and dilution concerns, alongside FDA approval for updated 2026–2027 COVID-19 vaccines.
- The broader market is lower, so macro sentiment does not explain Moderna’s advance.